{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:25:58Z","timestamp":1740162358342,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s11096-021-01355-7","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T20:53:41Z","timestamp":1638305621000},"page":"389-398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring co-dispensed drug use in patients on sevelamer or polystyrene sulfonate to identify potential novel binding interactions: a cross sectional in silico study"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3643-6706","authenticated-orcid":false,"given":"I. R. F.","family":"van Berlo \u2013 van de Laar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Prins\u2013Can","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. C. M.","family":"Schuiling-Veninga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Taxis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. G. A.","family":"Jansman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,30]]},"reference":[{"key":"1355_CR1","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1001\/jama.2019.14745","volume":"322","author":"TK Chen","year":"2019","unstructured":"Chen TK, Knicely DH, Grams ME. Chronic Kidney disease diagnosis and management. JAMA. 2019;322:1294\u2013304.","journal-title":"JAMA"},{"key":"1355_CR2","unstructured":"https:\/\/kdigo.org\/wp-content\/uploads\/2017\/02\/KDIGO_2012_CKD_GL.pdf. Accessed 11.11.2019"},{"key":"1355_CR3","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/ckj\/sfz046","volume":"12","author":"IM Schmidt","year":"2019","unstructured":"Schmidt IM, Hubner S, Nadal J, et al. Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German Chronic Kidney Disease study. Clin Kidney J. 2019;12:663\u201372.","journal-title":"Clin Kidney J"},{"key":"1355_CR4","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1111\/bcp.13738","volume":"84","author":"SM Laville","year":"2018","unstructured":"Laville SM, Metzger M, Stengel B, et al. Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD-REIN cohort. Br J Clin Pharmacol. 2018;84:2811\u201323.","journal-title":"Br J Clin Pharmacol"},{"key":"1355_CR5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12882-016-0317-4","volume":"17","author":"R Al-Ramahi","year":"2016","unstructured":"Al-Ramahi R, Raddad AR, Rashed AO, et al. Evaluation of potential drug-drug interactions among Palestinian hemodialysis patients. BMC Nephrol. 2016;17:96\u2013101.","journal-title":"BMC Nephrol"},{"key":"1355_CR6","first-page":"125","volume":"9","author":"OJ Fasipe","year":"2017","unstructured":"Fasipe OJ, Akhideno PE, Nwaiwu O, et al. Assessment of prescribed medications and pattern of distribution for potential drug-drug interactions among chronic kidney disease patients attending the Nephrology Clinic of lagos University Teaching Hospital in Sub-Saharan West Africa. Clin Pharmacol. 2017;9:125\u201332.","journal-title":"Clin Pharmacol"},{"key":"1355_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5935\/0101-2800.20140006","volume":"36","author":"AB Marquito","year":"2014","unstructured":"Marquito AB, Da Silva Fernandes NM, et al. Identifying potential drug interactions in chronic kidney disease patients. J Bras Nefrol. 2014;36:26\u201334.","journal-title":"J Bras Nefrol"},{"key":"1355_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40266-020-00747-0","volume":"37","author":"J Sommer","year":"2020","unstructured":"Sommer J, Seeling A, Rupprecht H. Adverse Drug Events in patients with Chronic Kidney Disease Associated with Multiple Drug Interactions and Polypharmacy. Drugs Aging. 2020;37:359\u201372.","journal-title":"Drugs Aging"},{"key":"1355_CR9","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/pharmaceutics12080713","volume":"12","author":"G Santos-Diaz","year":"2020","unstructured":"Santos-Diaz G, Perez-Pico AM, Suarez-Santisteban MA, et al. Prevalence of potential drug\u2013drug interaction risk among chronic kidney disease patients in a Spanish hospital. Pharmaceutics. 2020;12:713\u201324.","journal-title":"Pharmaceutics"},{"key":"1355_CR10","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/ki.2013.185","volume":"84","author":"JB Cannata-Andia","year":"2013","unstructured":"Cannata-Andia JB, Fernandez-Martin JL, Locatelli F, et al. Use of phosphate binding agents is associated with a lower risk of mortality. Kidney Int. 2013;84:998\u20131008.","journal-title":"Kidney Int"},{"key":"1355_CR11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.nefro.2018.05.003","volume":"38","author":"JB Sanjuan","year":"2018","unstructured":"Sanjuan JB, Navarro-Gonzalez JF, Arenas MD, et al. Pharmacological interactions of phosphate binders. Nefrologia. 2018;38:573\u20138.","journal-title":"Nefrologia"},{"key":"1355_CR12","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.2215\/CJN.13091216","volume":"12","author":"H Komaba","year":"2017","unstructured":"Komaba H, Wang M, Taniguchi M, et al. Initiation of Sevelamer and Mortality among Hemodialysis Patients treated with Calcium-based Phosphate Binders. Clin J Am Soc Nephrol. 2017;12:1489\u201397.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1355_CR13","unstructured":"www.ema.europa.eu\/en\/documents\/product-information\/renagel-epar-product-information_nl.pdf. Accessed 11.11.2019"},{"key":"1355_CR14","unstructured":"www.geneesmiddeleninformatiebank.nl\/smpc\/h10261_smpc.pdf. Accessed 11.11.2019"},{"key":"1355_CR15","unstructured":"www.geneesmiddeleninformatiebank.nl\/smpc\/h08071_smpc.pdf. Accessed 11.11.2019"},{"key":"1355_CR16","unstructured":"www.gipdatabank.nl\/databank?infotype=g&label=00-totaal&tabel=B_01-basis&geg=ddd&item=V03AE. Accessed 21.10.2021"},{"key":"1355_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12882-018-0947-9","volume":"19","author":"E Cataldo","year":"2018","unstructured":"Cataldo E, Columbano V, Nielsen L, et al. Phosphate binders as a cause of hypothyroidism in dialysis patients: pratical indications from a review of the literature. BMC Nephrol. 2018;19:155.","journal-title":"BMC Nephrol"},{"key":"1355_CR18","doi-asserted-by":"crossref","unstructured":"Kays MB, Overholser BR, Mueller BA et al. Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailibility of ciprofloxacin. Am J Kidney Dis 2003:;42:1253\u20131259","DOI":"10.1053\/j.ajkd.2003.08.027"},{"key":"1355_CR19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1159\/000447600","volume":"44","author":"SM Sprague","year":"2016","unstructured":"Sprague SM, Covic AC, Floege J, et al. Pharmacodynamic effects of sucroferric oxyhydroxide and sevelamer carbonate on vitamin D receptor agonist bioactivity in dialysis patients. Am J Nephrol. 2016;44:104\u201312.","journal-title":"Am J Nephrol"},{"key":"1355_CR20","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/ndt\/gfq598","volume":"26","author":"D Pierce","year":"2011","unstructured":"Pierce D, Hossack S, Poole L, et al. The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. Nephrol Dial Transplant. 2011;26:1615\u201321.","journal-title":"Nephrol Dial Transplant"},{"key":"1355_CR21","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/01.tp.0000172220.41719.31","volume":"80","author":"M Merkle","year":"2005","unstructured":"Merkle M, Wornle M, Rupprecht HD. The Effect of Sevelamer on Tacrolimus Target Levels. Transplantation. 2005;80:707.","journal-title":"Transplantation"},{"key":"1355_CR22","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1093\/ndt\/gfh446","volume":"19","author":"AK Pieper","year":"2004","unstructured":"Pieper AK, Buhle F, Bauer S, et al. The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. Nephrol Dial Transplant. 2004;19:2630\u20133.","journal-title":"Nephrol Dial Transplant"},{"key":"1355_CR23","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/jcpt.12265","volume":"40","author":"RHL Hoge","year":"2015","unstructured":"Hoge RHL, Arbouw MEL, Radstake DWS, et al. Subtherapeutic serum quetiapine concentrations after absorption inhibition by binding resins: a case report. J Clin Pharm Ther. 2015;40:355\u20137.","journal-title":"J Clin Pharm Ther"},{"key":"1355_CR24","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1093\/ndt\/gfi020","volume":"20","author":"HWHA Fleuren","year":"2005","unstructured":"Fleuren HWHA, Kho Y, Schuurmans MMJ, et al. Drug interaction between sevelamer and furosemide. Nephrol Dial Transplant. 2005;20:2288\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"1355_CR25","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/S0196-0644(05)81893-1","volume":"21","author":"DR B\u00e9langer","year":"1992","unstructured":"B\u00e9langer DR, Tierney MG, Dickinson G. Effect of sodium polystyrene sulfonate on lithium bioavailability. Ann Emerg Med. 1992;21:1312\u20135.","journal-title":"Ann Emerg Med"},{"issue":"8855","key":"1355_CR26","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/0140-6736(93)91195-R","volume":"341","author":"M McLean","year":"1993","unstructured":"McLean M, Kirkwood I, Epstein M, et al. Cation-exchange resin and inhibition of intestinal absorption of thyroxine. Lancet. 1993;341(8855):1286.","journal-title":"Lancet"},{"key":"1355_CR27","unstructured":"www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-recommends-separating-dosing-potassium-lowering-drug-sodium. Accessed 11.11.2019"},{"key":"1355_CR28","unstructured":"www.coreon.org\/wp-content\/uploads\/2020\/05\/coreon-gedragscode-gezondheidsonderzoek.pdf. Accessed 21.10.2021"},{"key":"1355_CR29","doi-asserted-by":"crossref","unstructured":"Visser ST, Schuiling-Veninga CM, Bos JHJ et al. The population-based prescription database IADB.nl: its development, usefulness in outcomes and research and challenges. Expert rev. Pharmacoecon. Outcomes Res 2013;13:285\u2013292","DOI":"10.1586\/erp.13.20"},{"key":"1355_CR30","doi-asserted-by":"crossref","unstructured":"Sediq R, Schans van der J, Dotinga A et al. Concordance assessment of self-reported medication use in the Netherlands three-generation Lifelines Cohort study with the pharmacy database iaDB.nl: the Pharmlines initiative. Clin Epidemiol 2018;10:981\u2013989","DOI":"10.2147\/CLEP.S163037"},{"key":"1355_CR31","unstructured":"www.whocc.no\/atc_ddd_index. Accessed 21.10\u20132021"},{"key":"1355_CR32","first-page":"93","volume":"41","author":"S Burke","year":"2001","unstructured":"Burke S, Amin N, Incerti C, et al. Sevelamer Hydrochloride (Renagel), a Nonabsorbed Phosphate-Binding Polymer, Does Not Interfere with Digoxin or Warfarin Pharmacokinetics. J Clin Pharmacol. 2001;41:93\u2013198.","journal-title":"J Clin Pharmacol"},{"key":"1355_CR33","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1177\/00912700122009881","volume":"41","author":"SK Burke","year":"2001","unstructured":"Burke SK, Amin NS, Incerti C, et al. Sevelamer Hydrochloride (Renagel\u00ae), a Phosphate-Binding Polymer, Does Not Alter the Pharmacokinetics of Two Commonly Used Antihypertensives in Healthy Volunteers. J Clin Pharmacol. 2001;41:199\u2013205.","journal-title":"J Clin Pharmacol"},{"key":"1355_CR34","unstructured":"https:\/\/go.drugbank.com. Accessed 01.06.2020"},{"key":"1355_CR35","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1177\/0091270009340783","volume":"49","author":"JR Walker","year":"2009","unstructured":"Walker JR, Brown K, Rohatagi S, et al. Quantitative Structure-Property Relationships Modeling to Predict in Vitro and in Vivo Binding of Drugs to the Bile Sequestrant, Colesevelam (Welchol). J Clin Pharmacol. 2009;49:1185\u201395.","journal-title":"J Clin Pharmacol"},{"key":"1355_CR36","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1124\/jpet.104.076182","volume":"314","author":"HH Usansky","year":"2005","unstructured":"Usansky HH, Sinko PJ. Estimating Human Drug Oral Absorption Kinetics From Caco-2 Permeability Using an Absorption-Disposition Model: Model Development and Evaluation and Derivation of Analytical Solutions for K(a) and F(a). J Pharmacol Exp Ther. 2005;314:391\u20139.","journal-title":"J Pharmacol Exp Ther"},{"key":"1355_CR37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jbi.2017.04.021","volume":"70","author":"R Ferdousi","year":"2017","unstructured":"Ferdousi R, Safdari R, Omidi Y. Computational prediction of drug-drug interactions based on drugs functional similarities. J Biomed Inform. 2017;70:54\u201364.","journal-title":"J Biomed Inform"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-021-01355-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-021-01355-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-021-01355-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T09:26:22Z","timestamp":1649928382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-021-01355-7"}},"subtitle":["Potential novel binding interactions with resins"],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1355"],"URL":"https:\/\/doi.org\/10.1007\/s11096-021-01355-7","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"type":"print","value":"2210-7703"},{"type":"electronic","value":"2210-7711"}],"subject":[],"published":{"date-parts":[[2021,11,30]]},"assertion":[{"value":"21 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}